214 related articles for article (PubMed ID: 32557982)
1. CAIXplatins: Highly Potent Platinum(IV) Prodrugs Selective Against Carbonic Anhydrase IX for the Treatment of Hypoxic Tumors.
Cao Q; Zhou DJ; Pan ZY; Yang GG; Zhang H; Ji LN; Mao ZW
Angew Chem Int Ed Engl; 2020 Oct; 59(42):18556-18562. PubMed ID: 32557982
[TBL] [Abstract][Full Text] [Related]
2. Emerging platinum(iv) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment.
Wang Z; Deng Z; Zhu G
Dalton Trans; 2019 Feb; 48(8):2536-2544. PubMed ID: 30633263
[TBL] [Abstract][Full Text] [Related]
3. A Carbonic Anhydrase IX (CAIX)-Anchored Rhenium(I) Photosensitizer Evokes Pyroptosis for Enhanced Anti-Tumor Immunity.
Su X; Wang WJ; Cao Q; Zhang H; Liu B; Ling Y; Zhou X; Mao ZW
Angew Chem Int Ed Engl; 2022 Feb; 61(8):e202115800. PubMed ID: 34842317
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-Activated Prodrug Derivatives of Carbonic Anhydrase Inhibitors in Benzenesulfonamide Series: Synthesis and Biological Evaluation.
Anduran E; Aspatwar A; Parvathaneni NK; Suylen D; Bua S; Nocentini A; Parkkila S; Supuran CT; Dubois L; Lambin P; Winum JY
Molecules; 2020 May; 25(10):. PubMed ID: 32443462
[TBL] [Abstract][Full Text] [Related]
5. CAIX furthers tumour progression in the hypoxic tumour microenvironment of esophageal carcinoma and is a possible therapeutic target.
Drenckhan A; Freytag M; Supuran CT; Sauter G; Izbicki JR; Gros SJ
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1024-1033. PubMed ID: 29865880
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models.
Ward C; Meehan J; Mullen P; Supuran C; Dixon JM; Thomas JS; Winum JY; Lambin P; Dubois L; Pavathaneni NK; Jarman EJ; Renshaw L; Um IH; Kay C; Harrison DJ; Kunkler IH; Langdon SP
Oncotarget; 2015 Sep; 6(28):24856-70. PubMed ID: 26259239
[TBL] [Abstract][Full Text] [Related]
7. Development of a Small Molecule Tubulysin B Conjugate for Treatment of Carbonic Anhydrase IX Receptor Expressing Cancers.
Marks IS; Gardeen SS; Kurdziel SJ; Nicolaou ST; Woods JE; Kularatne SA; Low PS
Mol Pharm; 2018 Jun; 15(6):2289-2296. PubMed ID: 29715036
[TBL] [Abstract][Full Text] [Related]
8. Cobalt Bis(dicarbollide) Alkylsulfonamides: Potent and Highly Selective Inhibitors of Tumor Specific Carbonic Anhydrase IX.
Grüner B; Kugler M; El Anwar S; Holub J; Nekvinda J; Bavol D; Růžičková Z; Pospíšilová K; Fábry M; Král V; Brynda J; Řezáčová P
Chempluschem; 2021 Mar; 86(3):352-363. PubMed ID: 32955786
[TBL] [Abstract][Full Text] [Related]
9. Targeting carbonic anhydrase IX improves the anti-cancer efficacy of mTOR inhibitors.
Faes S; Planche A; Uldry E; Santoro T; Pythoud C; Stehle JC; Horlbeck J; Letovanec I; Riggi N; Datta D; Demartines N; Dormond O
Oncotarget; 2016 Jun; 7(24):36666-36680. PubMed ID: 27153561
[TBL] [Abstract][Full Text] [Related]
10. NIR phosphorescent cyclometalated platinum (II) complexes with CAIX targeted and nuclear penetration as potent anticancer theragnostic agents.
Yang J; Chen DL; Wang PC; Yang B; Gao CZ
Eur J Med Chem; 2022 Dec; 243():114702. PubMed ID: 36084533
[TBL] [Abstract][Full Text] [Related]
11. Targeting ROS-AMPK pathway by multiaction Platinum(IV) prodrugs containing hypolipidemic drug bezafibrate.
Qiao X; Gao YY; Zheng LX; Ding XJ; Xu LW; Hu JJ; Gao WZ; Xu JY
Eur J Med Chem; 2021 Nov; 223():113730. PubMed ID: 34388483
[TBL] [Abstract][Full Text] [Related]
12. An unsymmetric cisplatin-based Pt(iv) derivative containing 2-(2-propynyl)octanoate: a very efficient multi-action antitumor prodrug candidate.
Gabano E; Ravera M; Zanellato I; Tinello S; Gallina A; Rangone B; Gandin V; Marzano C; Bottone MG; Osella D
Dalton Trans; 2017 Oct; 46(41):14174-14185. PubMed ID: 28984330
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Carbonic Anhydrase IX by Ureidosulfonamide Inhibitor U104 Reduces Prostate Cancer Cell Growth, But Does Not Modulate Daunorubicin or Cisplatin Cytotoxicity.
Riemann A; Güttler A; Haupt V; Wichmann H; Reime S; Bache M; Vordermark D; Thews O
Oncol Res; 2018 Mar; 26(2):191-200. PubMed ID: 28631600
[TBL] [Abstract][Full Text] [Related]
14. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors.
Lou Y; McDonald PC; Oloumi A; Chia S; Ostlund C; Ahmadi A; Kyle A; Auf dem Keller U; Leung S; Huntsman D; Clarke B; Sutherland BW; Waterhouse D; Bally M; Roskelley C; Overall CM; Minchinton A; Pacchiano F; Carta F; Scozzafava A; Touisni N; Winum JY; Supuran CT; Dedhar S
Cancer Res; 2011 May; 71(9):3364-76. PubMed ID: 21415165
[TBL] [Abstract][Full Text] [Related]
15. Novel carbonic anhydrase IX-targeted therapy enhances the anti-tumour effects of cisplatin in small cell lung cancer.
Bryant JL; Gieling RG; Meredith SL; Allen TJ; Walker L; Telfer BA; Supuran CT; Williams KJ; White A
Int J Cancer; 2018 Jan; 142(1):191-201. PubMed ID: 28905987
[TBL] [Abstract][Full Text] [Related]
16. A Cancer Cell-Selective and Low-Toxic Bifunctional Heterodinuclear Pt(IV)-Ru(II) Anticancer Prodrug.
Ma L; Lin X; Li C; Xu Z; Chan CY; Tse MK; Shi P; Zhu G
Inorg Chem; 2018 Mar; 57(5):2917-2924. PubMed ID: 29436828
[TBL] [Abstract][Full Text] [Related]
17. [The role of carbonic anhydrase IX in the progression of malignant tumors - a potential therapeutic target?].
Matolay O; Bádon SE; Balázs L; Juhász P; Csonka T; Méhes G
Magy Onkol; 2021 Jun; 65(2):157-166. PubMed ID: 34081763
[TBL] [Abstract][Full Text] [Related]
18. Biological evaluation of p-toluene sulphonylhydrazone as carbonic anhydrase IX inhibitors: An approach to fight hypoxia-induced tumors.
Queen A; Khan P; Idrees D; Azam A; Hassan MI
Int J Biol Macromol; 2018 Jan; 106():840-850. PubMed ID: 28830777
[TBL] [Abstract][Full Text] [Related]
19. Discovery of new 2, 5-disubstituted 1,3-selenazoles as selective human carbonic anhydrase IX inhibitors with potent anti-tumor activity.
Angeli A; Trallori E; Ferraroni M; Di Cesare Mannelli L; Ghelardini C; Supuran CT
Eur J Med Chem; 2018 Sep; 157():1214-1222. PubMed ID: 30193219
[TBL] [Abstract][Full Text] [Related]
20. Dual-tail arylsulfone-based benzenesulfonamides differently match the hydrophobic and hydrophilic halves of human carbonic anhydrases active sites: Selective inhibitors for the tumor-associated hCA IX isoform.
Ibrahim HS; Allam HA; Mahmoud WR; Bonardi A; Nocentini A; Gratteri P; Ibrahim ES; Abdel-Aziz HA; Supuran CT
Eur J Med Chem; 2018 May; 152():1-9. PubMed ID: 29684705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
